Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
研究单位：[1]Merck Sharp & Dohme LLC[2]Mid Florida Hematology and Oncology Center ( Site 0005),Orange City,Florida,United States,32763[3]Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003),Marietta,Georgia,United States,30060[4]Astera Cancer Care ( Site 0032),East Brunswick,New Jersey,United States,08816[5]Millennium Research & Clinical Development ( Site 0035),Houston,Texas,United States,77090[6]Instituto Alexander Fleming ( Site 0307),Ciudad Autónoma de Buenos Aires,Buenos Aires,Argentina,C1426ANZ[7]Hospital Británico de Buenos Aires-Oncology ( Site 0304),Ciudad autónoma de Buenos Aires,Caba,Argentina,C1280AEB[8]Centro Privado de RMI Río Cuarto S.A. II ( Site 0310),Río Cuarto,Cordoba,Argentina,X5800ALB[9]Instituto de Oncología de Rosario ( Site 0301),Rosario,Santa Fe,Argentina,S2000KZE[10]Clinica Adventista Belgrano-Oncology ( Site 0315),Caba,Argentina,1430[11]Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0303),La Rioja,Argentina,F5300COE[12]McGill University Health Centre ( Site 0204),Montréal,Quebec,Canada,H4A 3J1[13]Anhui Provincial Cancer Hospital ( Site 3132),Hefei,Anhui,China,230031[14]Beijing Cancer hospital ( Site 3100),Beijing,Beijing,China,100142[15]Beijing Peking Union Medical College Hospital-pneumology department ( Site 3107),Beijing,Beijing,China,100730[16]Chongqing University Cancer Hospital-Medical Oncology ( Site 3128),Chongqing,Chongqing,China,400030[17]Fujian Cancer Hospital ( Site 3124),Fuzhou,Fujian,China,350014[18]The First Affiliated hospital of Xiamen University ( Site 3125),Xiamen,Fujian,China,361003[19]Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine (,Guangzhou,Guangdong,China,510515[20]Guangxi Medical University Affiliated Tumor Hospital-Respiratory Oncology ( Site 3103),Nanning,Guangxi,China,530000[21]Hubei Cancer Hospital ( Site 3122),Wuhan,Hubei,China,430079[22]The Second Xiangya Hospital of Central South University-Oncology ( Site 3104),Changsha,Hunan,China,410011[23]Nanjing Drum Tower Hospital JiangBei International Branch Hospital ( Site 3117),Nanjing,Jiangsu,China,210008[24]The First Affiliated Hospital of Soochow University-Respiratory Department ( Site 3118),Suzhou,Jiangsu,China,215006[25]The Second Affiliated Hospital of Nanchang University ( Site 3119),Nanchang,Jiangxi,China,330006[26]Jinan Central Hospital ( Site 3113),Jinan,Shandong,China,250013[27]Sichuan Cancer hospital. ( Site 3127),Chengdu,Sichuan,China,610042[28]Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Medical Oncology ( Site 3106),Hangzhou,Zhejiang,China,310016[29]Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0601),Valledupar,Cesar,Colombia,200001[30]FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Sit,Bogota,Distrito Capital De Bogota,Colombia,110131[31]Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0606),Bogota,Distrito Capital De Bogota,Colombia,111321[32]Oncologos del Occidente ( Site 0604),Pereira,Risaralda,Colombia,660001[33]Fundacion Valle del Lili- CIC-Oncology CIC ( Site 0605),Cali,Valle Del Cauca,Colombia,760032[34]Nouvel Hôpital Civil (NHC) ( Site 1302),Strasbourg,Alsace,France,67091[35]Clinique Clairval ( Site 1306),Marseille,Bouches-du-Rhone,France,13009[36]Gustave Roussy ( Site 1303),Villejuif,Ile-de-France,France,94800[37]Hopitaux Universitaires Paris Centre-Hopital Cochin-Unité d'Oncologie Thoracique ( Site 1304),Paris,France,75014[38]Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1803),Milano,Lombardia,Italy,20141[39]Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800),Milan,Lombardia,Italy,20133[40]Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1804),Firenze,Toscana,Italy,50134[41]Fondazione Policli
研究目的：
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS).
